TOP STORY: Health Secretary Robert F. Kennedy Jr. says the Trump administration aims to create a regulated marketplace for peptides — "Americans are going to be buying these anyway. Our objective was to make sure that there is a regulated marketplace, so that what they're getting is what they claim to be, that is safe, that the factories are inspected." The sequel to the FDA's compounding-access policy story.

ACCESS VS. SAFETY: Apothecary Pharma's nationwide recall grows to 23 vials of compounded Tirzepatide plus one vial of NAD+ injection (Class II, no reported illnesses); Carolina Infusion's Class II recall of compounded Semaglutide, Tirzepatide, and Sermorelin syringes; an FDA warning letter to Empower Pharmacy; twenty state attorneys general warn about Chinese GLP-1 ingredients entering through the FDA's "Green List"; South Africa moves to tighten its compounding rules.

CONSUMER ECONOMICS: the GLP-1 supplement boom — a $74 billion market with no FDA preapproval requirement; plus one-liners on New Zealand premium food exports and GLP-1 costs vs. retirement savings.

PIPELINE: Ascletis posts positive preclinical data for a once-weekly oral amylin peptide pipeline; WuXi AppTec on why oral peptides can require 10–100x the drug ingredient.

BENEFITS RESEARCH: GLP-1 users with sleep apnea showed ~40% lower risk of acute respiratory failure (presented at CHEST 2026, not yet peer-reviewed).

For research and informational purposes only — not medical advice.

Sources:

- Reuters — "Kennedy says Trump administration aims for regulated market for peptides" (Oct 20, 2026): https://www.reuters.com/world/kennedy-says-trump-administration-aims-regulated-market-peptides-2026-10-20/

- Fox Business — Apothecary Pharma recall update, 23 vials incl. NAD+ injection (Oct 21, 2026)

- USA Today — "GLP-1 injections nationwide recall" (Oct 19, 2026): https://www.usatoday.com/story/money/consumer-protection/recalls-alerts/2026/10/19/glp-1-injections-nationwide-recall/92332991007/

- MedShadow — FDA Enforcement Report: Carolina Infusion compounded GLP-1 recalls (Oct 16, 2026): https://medshadow.org/drug-updates-recalls/fda-recalls-and-warnings/compounded-glp1-recalls-metoclopramide-tretinoin/

- FDA warning letter to Empower Pharmacy (dated Sept 18, 2026; public Sept 22, 2026)

- Regulatory Oversight / AL AG release — 20-state AGs letter on FDA "Green List" and Chinese GLP-1 ingredients (Oct 21, 2026)

- Reuters — "South Africa revises rules around customisation of weight-loss drugs" (Oct 14, 2026): https://www.reuters.com/legal/litigation/south-africa-revises-rules-around-customisation-weight-loss-drugs-2026-10-14/

- Reuters — "Weight-loss drug users turn to dietary supplements; doctors, regulators raise flags" (Oct 20, 2026): https://www.reuters.com/legal/litigation/weight-loss-drug-users-turn-dietary-supplements-doctors-regulators-raise-flags-2026-10-20/

- RNZ — "Rise of GLP-1 unlocking new opportunities for New Zealand's premium food exports" (Oct 19, 2026): https://www.rnz.co.nz/news/country/2036071/rise-of-glp-1-unlocking-new-opportunities-for-new-zealand-s-premium-food-exports

- Benefit News / Nationwide Retirement Institute survey — GLP-1 costs vs. retirement savings (Oct 21, 2026)

- PR Newswire via Morningstar — "Ascletis announces positive preclinical data for the most comprehensive once-weekly oral peptide pipeline" (Oct 19, 2026): https://www.morningstar.com/news/pr-newswire/20261019cn75171/ascletis-announces-positive-preclinical-data-for-the-most-comprehensive-once-weekly-oral-peptide-pipeline-for-the-treatment-of-obesity

- GlobeNewswire — "Peptide manufacturing trends: how oral dosing raises API demand" (WuXi AppTec, Oct 21, 2026): https://www.globenewswire.com/news-release/2026/10/21/3385365/0/en/peptide-manufacturing-trends-how-oral-dosing-raises-api-demand.html

- Medical Daily — "GLP-1, sleep apnea, acute respiratory failure" (CHEST 2026 presentation, Oct 19, 2026): https://www.medicaldaily.com/glp-1-sleep-apnea-acute-respiratory-failure-chest-2026-480137

A Spoke-Media production:

https://www.spoke-media.com

Peptide Overview:

A comprehensive walkthrough of "Peptides: small wonder?", the expert view published by SCOR (one of the world's largest reinsurance companies).

Jake and Cynthia cover what peptides actually are, who's using them and why — from GLP-1s to BPC-157 — the four ways people obtain them, the six categories of risk, how they compare to other drugs, and what it all means in plain language. Ends with a simplified overview tying it together.

For research and informational purposes only — not medical advice.

**Sources:**

- SCOR — "Peptides: small wonder?" Expert View (September 2026): https://www.scor.com/en/expert-views/peptides-small-wonder

A Spoke-Media production:

https://www.spoke-media.com

This week: BPC-157, the most talked-about healing peptide on the internet — a 15-amino-acid fragment from human gastric juice with thirty years of animal research and encouraging reports, but yet to be proven in human trials.

Jake and Cynthia unpack the mechanism (angiogenesis, fibroblast activity, gut-barrier repair), the striking tendon/ligament/gut data in animals, the real evidence gap, and the July 2026 FDA advisory vote everyone is misreading.

Plus the GLP pulse: the FDA's interim peptide-compounding policy names BPC-157, Europe's regulator backs Lilly's oral GLP-1 Foundayo, and Biomea posts Phase 1 data for its oral small-molecule BMF-650.

For research and informational purposes only — not medical advice. Nothing on this show is a recommendation for any product or treatment.

**Sources:**

- Reuters — FDA/HHS submit interim peptide-compounding policy for White House review (Oct 15): https://www.reuters.com/legal/litigation/us

-fda-takes-step-change-peptide-compounding-policy-2026-10-15/

- AP via Stocktwits — BPC-157 named in compounding policy reporting; Hims stock +6% (Oct 15): https://stocktwits.com/news-articles/markets/equity/hims-stock-peptide-hopes-trump-administration-reviews-plan-unlock-market/cZx0VkeRBr8

- EMA — CHMP recommends EU approval for Foundayo/orforglipron (Oct 16): https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-october-2026

- Reuters — Lilly's Foundayo wins European backing (Oct 16): https://www.reuters.com/legal/litigation/eli-lillys-weight-loss-pill-wins-backing-europe-2026-10-16/

- GlobeNewswire — Biomea Phase 1 results for oral small-molecule GLP-1 BMF-650 (Oct 13): https://www.globenewswire.com/news-release/2026/10/13/3380154/0/en/biomea-fusion-announces-phase-1-results-for-bmf-650-its-investigational-next-generation-oral-small-molecule-glp-1-receptor-agonist.html

- Brainflow — BPC-157 complete guide (2025 AAOS systematic review, 39 studies): https://brainflow.co/complete-guide-to-BPC-157-benefits-dosage/

- Marketing or Science — BPC-157 evidence vs hype, July 2026 PCAC vote: https://marketingorscience.com/articles/pharma/2026/07/BPC-157-healing-peptide

- Lambert Medical Practice — BPC-157 peptide guide (mechanisms, gut/tendon data): https://lambertmedicalpractice.co.uk/blog/BPC-157-peptide-guide/

- Top Doctor Magazine — PCAC vote 8–6, ulcerative colitis indication: https://topdoctormagazine.com/news/regenerative-medicine-peptide-evidence-hype/

- OneDayMD — clinician peptide guide (PCAC six-of-seven, regulatory status): https://www.onedaymd.com/2026/02/peptides-guide.html

- Frier Levitt — PCAC 503A legal analysis (advisory vs binding): https://www.frierlevitt.com/news/fda-pcac-peptides-503a-compounding/

- Blog by Donna — PCAC vote explainer ("recommendation is not a rule"): https://blogbydonna.com/the-fda-peptide-vote-didnt-legalize-BPC-157/

A Spoke-Media production:

https://www.spoke-media.com